Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 124

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 124
---
, net6,566 6,684 All other corporate assets5,695 5,446  $40,140 $39,395 

29

As ofLong-lived assets (in millions)March 31, 2025December 31, 2024U.S.$1,522 $1,461 Ireland655 631 Costa Rica557 530 Other countries654 672 Property, plant and equipment, net3,389 3,294 Goodwill17,340 17,089 Other intangible assets, net6,566 6,684 Operating lease right-of-use assets in Other long-term assets448 449  $27,743 $27,516 

NOTE K – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.Three Months Ended March 31,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$420 $253 $673 $395 $247 $642 Urology469 165 633 356 157 513 Neuromodulation204 67 271 190 66 256 MedSurg1,093 484 1,577 941 470 1,412    Interventional Cardiology Therapies232 465 697 195 457 652    Watchman390 34 425 311 33 344    Cardiac Rhythm Management358 220 578 354 221 575     Electrophysiology511 219 730 158 143 300 Cardiology1,491 938 2,429 1,017 854 1,872 Peripheral Interventions376 280 656 299 274 573 Cardiovascular1,868 1,218 3,085 1,316 1,129 2,445 Total Net Sales$2,960 $1,702 $4,663 $2,258 $1,599 $3,856 Refer to Note